Aegon posts stronger H1 as U.S. transition advances

Transcript intelligence

What changed

Compared with the prior analysis, Aegon reported operating results up 9% to EUR 804 million and new life sales up 54%, increased its buyback program by EUR 150 million and raised the interim dividend by 11%. The U.S. transition became more concrete through the UK sale, planned Transamerica rebrand and New York relocation; a CFO search also began.

Guidance delta

Guidance sentiment was maintained. Management said new-business strain and assumption updates are being managed to maintain operating capital-generation targets.

Key takeaways

• Operating results rose 9% year over year to EUR 804 million, with free cash flow of EUR 392 million.
• New life sales increased 54%, supported by digital instant-decision products and faster underwriting.
• The company increased its share-buyback program by EUR 150 million and raised its interim dividend by 11%.
• Aegon is progressing its U.S. transition, including the sale of Aegon UK and planned rebranding to Transamerica.
• New-business strain, assumption updates, long-term-care capital and the CFO transition remain key watchpoints.

Management priorities

• Complete the U.S. relocation and New York head-office setup by early 2028
• Implement U.S. GAAP, including dry runs in the second half of 2026
• Accelerate in-force earnings to offset new-business strain
• Continue share buybacks and dividend growth
• Search for and appoint a new CFO